Side Effects and Safety of Sandimmun® in Long-term Treatment of Transplant Patients

  • P. Krupp
  • P. Timonen
  • A. Gülich


The introduction of Sandimmun® (ciclosporin) into immunosuppressive therapy has improved the results of organ transplantation with respect to patient survival, graft survival and the main post-transplant complications [5, 6, 16, 26], and the adverse reaction profile of this potent immunosuppressive agent has been established [7]. However, long-term safety experience is still limited. To broaden knowledge in this respect, a long-term safety follow-up, primarily of bone marrow and renal transplant recipients treated with Sandimmun, has been initiated. Preliminary data of this ongoing investigation from renal transplant recipients, who provide the bulk of the information, are presented here.


Transplant Recipient Graft Survival Renal Transplant Recipient Kidney Transplant Recipient Cadaveric Renal Transplantation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Beveridge T, Krupp P, McKibbin C (1984) Lymphomas and lymphoproliferative lesions developing under cyclosporin therapy. Lancet 1:788PubMedCrossRefGoogle Scholar
  2. 2.
    Birkeland SA (1983) Malignant tumors in renal transplant patients. The Scandia transplant material. Cancer 51:1571–1575PubMedCrossRefGoogle Scholar
  3. 3.
    Borel JF, Bauer C, Gubler HU et al. (1976) Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 6:468–475PubMedCrossRefGoogle Scholar
  4. 4.
    Borel JF (1984) Animal experiments with ciclosporin. Triangle 23: 3/4, 153Google Scholar
  5. 5.
    Caine RY, White DJG, Evans DB et al. (1981) Cyclosporin A in cadaveric organ transplantation. Br Med J 282:934CrossRefGoogle Scholar
  6. 6.
    Canadian Multicentre Transplant Study Group (1983) A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 309:809–815CrossRefGoogle Scholar
  7. 7.
    Cohen DJ, Loertscher R, Rubin MF et al. (1984) Cyclosporine: A new immunosuppressive agent for organ transplantation. Ann Intern Med 101:667–682PubMedGoogle Scholar
  8. 8.
    Handelsman DJ, McDowell IFW, Caterson ID (1984) Ovarian function after renal transplantation: comparison on cyclosporin A with azathioprine and prednisone combination regimens. Br J Obstet Gynaecol 91:802–807PubMedCrossRefGoogle Scholar
  9. 9.
    Handelsman DJ, McDowell IFW, McDowell W et al. (1984) Testicular function after renal transplantation: comparison of Cyclosporin A with azathioprine and prednisone combination regimes. Clin Nephrol 22: No. 3, 144–148PubMedGoogle Scholar
  10. 10.
    Hess AD (1985) Effect of interleukin 2 on the immunosuppressive action of cyclosporine. Transplantation 39:62–68PubMedCrossRefGoogle Scholar
  11. 11.
    Jacobs C, Brunner FP, Brynger H et al. (1981) Malignant diseases in patients treated by dialysis and transplantation in Europe. Transplant Proc 13:729–732PubMedGoogle Scholar
  12. 12.
    Kahan BD, Ried M, Newburger J (1983) Pharmacokinetics of cyclosporine in human renal transplantation. Transplant Proc 15:446–453Google Scholar
  13. 13.
    Keown PA, Stiller CR, Ulan RA et al. (1981) Immunological and pharmacological monitoring in the clinical use of cyplosporin A. Lancet 1:686–689PubMedCrossRefGoogle Scholar
  14. 14.
    Kinlen LJ, Sheil AGR, Peto J, Doll R (1979) Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 2:1461 –1466PubMedCrossRefGoogle Scholar
  15. 15.
    Mangal AK, Growe GH, Sinclair M et al. (1984) Acquired hemolytic anemia due to Side Effects and Safety of Sandimmun in Long-term Treatment of Transplant Patients 49 “auto”-anti-A or “auto”-anti-B induced by group 0 homograft in renal transplant recipients. Transfusion 24:201–205PubMedCrossRefGoogle Scholar
  16. 16.
    Merion RM, David MD, White DJG et al. 22. (1984) Cyclosporine: Five years’ experience in cadaveric renal transplantation. N Engl J Med 310:148–154PubMedCrossRefGoogle Scholar
  17. 17.
    Mihatsch JM, Thiel G, Ryffel B (1985) 23. Ciclosporin-associated Nephropathy. In: Schindler R (ed) Ciclosporin in Autoimmune Diseases. 1st International Symposium, Basle, March 18–20, 1985. Springer, Berlin 24. Heidelberg New York Tokyo, p 50Google Scholar
  18. 18.
    Najarian JS, Ferguson RM, Sutherland DER et al. (1983) A prospective trial of the ef- 25. ficacy of cyclosporine in renal transplantation at the University of Minnesota. Transplant Proc 15: No. 1, 438–441Google Scholar
  19. 19.
    Oyer PE, Stinson EB, Jamieson SW et al. (1984) Cyclosporine in cardiac transplan- 26. tation: A 2Y2 year follow-up. In: B. D. Kahan, Cyclosporine, Vol. 1, Biological Activity and Clinical Applications. Grune and Stratton, Orlando, p 330–336 27.Google Scholar
  20. 20.
    Penn I (1970) Malignant tumors in organ transplant recipients. Springer, BerlinGoogle Scholar
  21. 21.
    Price CP, Deam SM, Calvin J (1983) Serum alkaline phosphatase isoenzyme in patients on cyclosporin A following renal transplantation. Clin Biochem 16, No. 5, Abstr. C314, A25Google Scholar
  22. 22.
    Reece IJ, Okereke OUJ, Painvin GA et al. (1984) Infection in cyclosporine-immunosuppressed cardiac allograft recipients. Heart Transplant 3:239–242Google Scholar
  23. 23.
    Sheil AGR, Mahony JF, Horvath JS et al. (1981) Cancer following successful cadaveric donor renal transplantation. Transplant Proc 13:733–735PubMedGoogle Scholar
  24. 24.
    Sheil AGR (1984) Cancer in organ transplant recipients: part of an induced immune deficiency syndrome. Br Med J 288:659–661CrossRefGoogle Scholar
  25. 25.
    Thiel G, Harder F, Loertscher R, et al. (1983) Cyclosporin A used alone or in combination with low-dose steroids in cadaveric renal transplantation. Klin Wochenschr 61:991 —1000Google Scholar
  26. 26.
    van Buren CT, Rechner SM, Kerman RH et al. (1984) Cyclosporine improves outcome in high-risk cadaveric renal allograft recipients. Transplant Proc 16:1162–1166PubMedGoogle Scholar
  27. 27.
    Vanrenterghem Y, Gresele P, Roels L et al. (1985) Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet 1:999–1002PubMedCrossRefGoogle Scholar

Copyright information

© Sandoz Ltd, Basle 1985

Authors and Affiliations

  • P. Krupp
    • 1
  • P. Timonen
    • 1
  • A. Gülich
    • 1
  1. 1.Clinical Research, Pharmaceutical DivisionSandoz LtdBasleSwitzerland

Personalised recommendations